#Thinksabio latest news
Nasus Pharma Announces Approval from Health Canada to Initiate Planned Phase 2 Clinical Study of NS002 Intranasal Epinephrine PowderPositive Regulatory Response Marks Important Milestone for NS002 Development Program
Nasus Pharma Announces Approval from Health Canada to Initiate Planned Phase 2 Clinical Study of NS002 Intranasal Epinephrine PowderPositive Regulatory Response Marks Important Milestone for NS002 Development Program